Novozymes A/S
NVZMF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.84 | -1.83 | 1.52 | 3.83 |
| FCF Yield | 0.37% | 2.09% | 1.14% | 1.89% |
| EV / EBITDA | 22.53 | 18.92 | 17.02 | 29.45 |
| Quality | ||||
| ROIC | 19.06% | 12.72% | 15.34% | 16.71% |
| Gross Margin | 52.00% | 54.32% | 54.63% | 57.78% |
| Cash Conversion Ratio | 3.34 | 1.37 | 1.09 | 1.29 |
| Growth | ||||
| Revenue 3-Year CAGR | 17.66% | 6.20% | 7.80% | 1.32% |
| Free Cash Flow Growth | -68.51% | 87.81% | -60.45% | -17.36% |
| Safety | ||||
| Net Debt / EBITDA | 0.19 | 1.17 | -0.02 | -0.10 |
| Interest Coverage | 48.91 | 171.17 | 44.72 | 39.28 |
| Efficiency | ||||
| Inventory Turnover | 19.04 | 2.26 | 2.09 | 2.11 |
| Cash Conversion Cycle | 18.18 | 100.81 | 99.71 | 159.79 |